BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
49.08
-1.15 (-2.29%)
At close: Aug 22, 2025, 4:00 PM
49.60
+0.52 (1.06%)
After-hours: Aug 22, 2025, 7:32 PM EDT
BridgeBio Pharma Revenue
BridgeBio Pharma had revenue of $110.57M in the quarter ending June 30, 2025, with 4,999.86% growth. This brings the company's revenue in the last twelve months to $235.81M, up 7.62% year-over-year. In the year 2024, BridgeBio Pharma had annual revenue of $221.90M with 2,285.27% growth.
Revenue (ttm)
$235.81M
Revenue Growth
+7.62%
P/S Ratio
39.48
Revenue / Employee
$323,030
Employees
730
Market Cap
9.38B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 221.90M | 212.60M | 2,285.27% |
Dec 31, 2023 | 9.30M | -68.35M | -88.02% |
Dec 31, 2022 | 77.65M | 7.93M | 11.38% |
Dec 31, 2021 | 69.72M | 61.47M | 745.14% |
Dec 31, 2020 | 8.25M | -32.31M | -79.66% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
BBIO News
- 14 days ago - BridgeBio Pharma, Inc. (BBIO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 18 days ago - BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 24 days ago - Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains. - Barrons
- 4 weeks ago - Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1 - GlobeNewsWire
- 4 weeks ago - BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET - GlobeNewsWire
- 7 weeks ago - BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty - GlobeNewsWire
- 2 months ago - BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET - GlobeNewsWire
- 2 months ago - BridgeBio: New Data Bolsters The Bull Case - Seeking Alpha